- Home
- MBIO vs RDHL Comparison
MBIO vs RDHL Comparison
Compare MBIO & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBIO
- RDHL
- Stock Information
- Founded
- MBIO 2015
- RDHL 2009
- Country
- MBIO United States
- RDHL Israel
- Employees
- MBIO N/A
- RDHL N/A
- Industry
- MBIO Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- MBIO Health Care
- RDHL Health Care
- Exchange
- MBIO Nasdaq
- RDHL Nasdaq
- Market Cap
- MBIO 4.7M
- RDHL 3.8M
- IPO Year
- MBIO N/A
- RDHL N/A
- Fundamental
- Price
- MBIO $1.24
- RDHL $2.00
- Analyst Decision
- MBIO
- RDHL
- Analyst Count
- MBIO 0
- RDHL 0
- Target Price
- MBIO N/A
- RDHL N/A
- AVG Volume (30 Days)
- MBIO 1.6M
- RDHL 20.0K
- Earning Date
- MBIO 08-12-2025
- RDHL 04-10-2025
- Dividend Yield
- MBIO N/A
- RDHL N/A
- EPS Growth
- MBIO N/A
- RDHL N/A
- EPS
- MBIO N/A
- RDHL N/A
- Revenue
- MBIO N/A
- RDHL $8,042,999.00
- Revenue This Year
- MBIO N/A
- RDHL $381.91
- Revenue Next Year
- MBIO N/A
- RDHL N/A
- P/E Ratio
- MBIO N/A
- RDHL N/A
- Revenue Growth
- MBIO N/A
- RDHL 23.17
- 52 Week Low
- MBIO $0.89
- RDHL $1.71
- 52 Week High
- MBIO $31.00
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- MBIO 50.75
- RDHL 55.20
- Support Level
- MBIO $0.89
- RDHL $1.75
- Resistance Level
- MBIO $2.13
- RDHL $2.08
- Average True Range (ATR)
- MBIO 0.16
- RDHL 0.10
- MACD
- MBIO 0.04
- RDHL 0.02
- Stochastic Oscillator
- MBIO 28.05
- RDHL 76.92
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.